
**CLAIMS**

1. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:



(I)

wherein:

W is O, N-H, N-($C_1$-$C_{10}$ alkyl) or S;

each X is independently CH or N;

$R^1$ is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O;

$R^2$ is LY;

each L is a direct bond, $C_1$-$C_{10}$ alkylene, $C_2$-$C_{10}$ alkenylene or $C_2$-$C_{10}$ alkynylene;

Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and

each $R^3$ is independently H, $C_1$-$C_{10}$ alkyl, halogen, fluoro $C_1$-$C_{10}$ alkyl, O-$C_1$-$C_{10}$ alkyl, NH-$C_1$-$C_{10}$ alkyl, S-$C_1$-$C_{10}$ alkyl, O-fluoro $C_1$-$C_{10}$ alkyl, NH-acyl, NH-C(O)-NH-$C_1$-$C_{10}$ alkyl, C(O)-NH-$C_1$-$C_{10}$ alkyl, aryl or heteroaryl.

2. The composition according to claim 1, wherein the compound according to formula I is in its succinate salt form.

3. The composition according to claim 1 or 2, further comprising a surfactant.

4. The composition according to any one of the preceding claims, wherein the composition is a solid dosage form.

5. The composition according to any one of the preceding claims, wherein the composition comprises at least two pharmaceutical excipients.

6. The composition according to any one of the preceding claims, wherein the compound according to formula I is present in an amount of from 0.1 to 50 wt% based on the total weight of the composition.

7. The composition according to any one of the preceding claims, wherein a filler is present in an amount of from 10 to 90 wt% based on the total weight of the composition.

8. The composition according to any one of the preceding claims, wherein a binder is present in an amount of from 0.1 to 20 wt% based on the total weight of the composition.

9. The composition according to any one of the preceding claims, wherein a disintegrant is present in an amount of from 1 to 20 wt% based on the total weight of the composition.

10. The composition according to any one of the preceding claims, wherein a lubricant is present in an amount of from 0.1 to 10 wt% based on the total weight of the composition.

11. The composition according to any one of the preceding claims, wherein the composition comprises:

1 to 50 wt% of a compound according to claim 1;


10 to 90 wt% of at least one filler;

0.1 to 20 wt% of at least one binder;

1 to 20 wt% of at least one disintegrant; and

0.1 to 10 wt% of at least one lubricant or glidant.

12. The composition according to any one of the preceding claims, wherein $R^1$ is represented by any of the following structures:




13. The composition according to any one of the preceding claims, wherein $R^1$ is morpholine.

14. The composition according to any one of the preceding claims, wherein W is O or S.

15. The composition according to any one of the preceding claims, wherein W is O.


16. The composition according any one of the preceding claims, wherein X is CH.

17. The composition according to any one of the preceding claims, wherein $R^3$ is H.


18. The composition according to any one of the preceding claims, wherein L is $C_1$-$C_{10}$ alkylene.

19. The composition according to any one of the preceding claims, wherein Y contains one or two heteroatoms.

20. The composition according to any one of the preceding claims, wherein Y is selected from:




Formula A




Formula B

or

wherein:

A is selected from O, S, $NR^4$ or optionally substituted $C_1$-$C_3$ alkylene, $C_2$-$C_3$ alkenylene or $C_2$-$C_3$ alkynylene;

B is $NR^4$, O or $CH_2$;

wherein $R^4$ is H or optionally substituted $C_1$-$C_{10}$ alkyl, $C_2$-$C_{10}$ alkenyl or $C_2$-$C_{10}$ alkynyl;

p is selected from 0 or 1;


each m is independently selected from 0, 1 or 2; and

each n is independently selected from 1, 2 or 3.

21. The composition according to claim 20, wherein A is O or $C_1$-$C_3$ alkylene.

22. The composition according to claim 20 or 21, wherein B is O or $CH_2$.

23. The composition according to any one of the preceding claims, wherein the compound according to formula I is illustrated by any one of the following structures:



24. A method for the manufacture of a pharmaceutical composition, according to any one of claims 1 to 23, comprising:

a) mixing a compound according to formula I with at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants to form a blend;

b) processing the blend into a pharmaceutical composition; and

c) compressing the composition of step (b) in to a tablet.

25. The method of claim 24, wherein step (b) further comprises screening to ensure a particle size of less than 1000 μm.

26. Use of a composition according to any of claims 1 to 23 in the manufacture of a medicament for use in therapy, wherein the therapy is of cancer, an immune disorder or an inflammatory disorder.

27. The use according to claim 26, wherein the cancer is a leukaemia or a PTEN-negative solid tumour.

28. The use according to claim 26 or claim 27, wherein the therapy is of rheumatoid arthritis.

29. The use according to claim 26, for use in anti-rejection therapy following an organ transplant.